Cipher Pharmaceuticals Inc
SWB:PHE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Cipher Pharmaceuticals Inc
SWB:PHE
|
CA |
|
C
|
Cipher Pharmaceuticals Inc
F:PHE
|
CA |
|
A
|
Abbott Laboratories
XMUN:ABL
|
US |
|
B
|
Boeing Co
DUS:BCO
|
US |
|
V
|
Vinci SA
F:SQU
|
FR |
Wall St Price Targets
PHE Price Targets Summary
Cipher Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for PHE is 12.31 EUR with a low forecast of 2.5 EUR and a high forecast of 13.84 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is PHE's stock price target?
Price Target
12.31
EUR
According to Wall Street analysts, the average 1-year price target for PHE is 12.31 EUR with a low forecast of 2.5 EUR and a high forecast of 13.84 EUR.
What is the Revenue forecast for Cipher Pharmaceuticals Inc?
Projected CAGR
8%
Over the last 13 years, the compound annual growth rate for Revenue has been 15%. The projected CAGR for the next 3 years is 8%.
What is the Gross Profit forecast for Cipher Pharmaceuticals Inc?
Projected CAGR
20%
The compound annual growth rate for Gross Profit over the next 3 years is 20%.
What is the Operating Income forecast for Cipher Pharmaceuticals Inc?
Projected CAGR
31%
Over the last 13 years, the compound annual growth rate for Operating Income has been 16%. The projected CAGR for the next 1 year is 31%.
What is the Pre-Tax Income forecast for Cipher Pharmaceuticals Inc?
Projected CAGR
31%
Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 16%. The projected CAGR for the next 3 years is 31%.
What is the Net Income forecast for Cipher Pharmaceuticals Inc?
Projected CAGR
9%
Over the last 13 years, the compound annual growth rate for Net Income has been 20%. The projected CAGR for the next 3 years is 9%.